undetectable plasma viral load on ART and with CD4 cell counts above 500/µL, who were tested for integrated virus (UND, n=38), as well as in ageand sex-matched viremic patients (VIR, n=18) and HIV-seronegative healthy donors (HD, n=20). The Kruskal-Wallis and Dunn tests were used for statistical analysis (** p < 0.01). Boxes represent the median and the 25 th and 75 th percentiles; whiskers represent the 10 th and 90 th percentiles. Table 1 for the characteristics of patients). Integrated HIV DNA was quantified in 38 patients (P1-P38) and virus production assay was performed in 7 patients (P39-P45). The time on ART with undetectable plasma virus, the CD4 and CD8 T cell counts in blood and the percentages of CD4 and CD8 T cells in blood at the time of sampling are indicated for each patient.
Supplementary Figure 8

Supplementary Methods
Proliferation assay: Sorted T SCM , T CM , T EM and T IM were stained with 0.5 µM CFSE (Invitrogen) and cultured in complete medium (RPMI with glutamax, antibiotics, pyruvate, 10% of human serum AB) with a mix of recall antigens [PPD (Statens Institut, 1 µg ml -1 ), TT (Statens Institut, 1/50), VZV, HSV (Tebu-Bio, each 1/50) and CMV (Virusys, 1/50)] for 5 days in the presence of autologous CD8-depleted PBMC (CD8 microbeads, Miltenyi). CFSE dilution was analyzed in each subset by flow cytometry.
Virus production: Sorted resting memory CD4+ T cell subsets were obtained from patients on ART from 34 to 148 months. From 100,000 to 250, 000 sorted cells were preactivated with PHA (1 µg ml -1 , Sigma-Aldrich) and IL-2 (10 ng ml -1 , R&D Systems) for 48 hours, then cultured for 21 days in the presence of PHA-activated allogenic CD8-depleted PBMC (CD8 microbeads, Miltenyi; ratio: 1/2.5). Half of the medium was removed three times a week and replaced by fresh medium containing IL-2. HIV RNA was quantified in the supernatants by quantitative RT-PCR (Cobas Amplicor HIV-1 Detector Kit, Roche Diagnostics, lower limit of quantitation: 20 copies per ml) on day 21. 
